Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.89 |
| ▸ | TNF | P01375 | 7/20 | 0.89 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.89 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.89 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.89 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.89 |
| ▸ | CIT | O14578 | 1/20 | 0.89 |
| ▸ | MUSK | O15146 | 1/20 | 0.89 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.89 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.89 |
| ▸ | STK10 | O94804 | 1/20 | 0.89 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.89 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.89 |
| ▸ | ABL1 | P00519 | 1/20 | 0.89 |
| ▸ | EGFR | P00533 | 1/20 | 0.89 |
| ▸ | RAF1 | P04049 | 1/20 | 0.89 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.89 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.89 |
| ▸ | PRKCB | P05771 | 1/20 | 0.89 |
| ▸ | LCK | P06239 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doramapimod SCHEMBL129721 | 0.94 | MAPK14 (1.00) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| Doramapimod SCHEMBL29353023 | 0.94 | MAPK14 (1.00) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| Doramapimod SCHEMBL10320344 | 0.93 | MAPK14 (0.98) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL295302 | 0.92 | MAPK14 (1.00) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL6330722 | 0.91 | MAPK14 (1.00) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL5967541 | 0.91 | MAPK14 (0.88) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL20876996 | 0.90 | MAPK14 (0.93) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL14185084 | 0.90 | MAPK14 (0.91) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL5967531 | 0.89 | MAPK14 (0.90) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL26051142 | 0.89 | MAPK14 (0.87) | MAPK14TNFMAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1709965-A2 | Methods of treating cytokine mediate diseases | Boehringer Ingelheim Pharmaceuticals, Inc. (US) | 2006-10-11 | — | — | EP | claimed |
| US-6916814-B2 | Methods of treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-07-12 | — | — | US | claimed |
| EP-1408950-A2 | METHODS OF TREATING CYTOKINE MEDIATED DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-04-21 | — | — | EP | claimed |
| US-6525046-B1 | Inhibits inflammatory cytokines such as interleukin-1 and tumor necrosis factor; 1-(5-(2-hydroxy-1,1-dimethyl-ethyl) -2-p-tolyl-2H-pyrazol-3-yl)-3- (4-(2- morpholin-4-yl-ethoxy)-naphthalen-1-yl)-urea | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-02-25 | — | — | US | claimed |
| WO-2003005999-A2 | METHODS OF TREATING CYTOKINE MEDIATED DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-01-23 | — | — | WO | claimed |
| EP-1709965-A2 | Methods of treating cytokine mediate diseases | Boehringer Ingelheim Pharmaceuticals, Inc. (US) | 2006-10-11 | — | — | EP | disclosed |
| US-6916814-B2 | Methods of treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-07-12 | — | — | US | disclosed |
| US-20040152725-A1 | Methods of treating cancer | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-08-05 | — | — | US | disclosed |
| US-20030130309-A1 | Methods of treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-07-10 | — | — | US | disclosed |
| US-6525046-B1 | Inhibits inflammatory cytokines such as interleukin-1 and tumor necrosis factor; 1-(5-(2-hydroxy-1,1-dimethyl-ethyl) -2-p-tolyl-2H-pyrazol-3-yl)-3- (4-(2- morpholin-4-yl-ethoxy)-naphthalen-1-yl)-urea | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130309-A1 | Methods of treating cytokine mediated diseases | IL2, IFNG, IL1A | MAPK14 3143/4885TNF 18/4885MAPK13 3752/4885 |
| US-20040152725-A1 | Methods of treating cancer | IL2, IL36G, IFNG | MAPK14 3691/4885TNF 54/4885MAPK13 4084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.